Chlortalidone

Thiazide-like Diuretic — CARDIOVASCULAR SYSTEM

Key facts

Chlortalidone is an ofp drug in the Thiazide-like Diuretic class catalogued in DrugCentral. It was first approved by the FDA in 1960. DrugCentral lists 14 molecular targets, including CA7, CA12 and CA5B. Recorded indications include Edema, Hypertensive disorder, Peripheral Edema due to Chronic Heart Failure and Pulmonary Edema due to Chronic Heart Failure.

• Approval status: ofp (first approved 1960 by the FDA).
• Drug class: Thiazide-like Diuretic.
• Molecular targets: CA7, CA12, CA5B and Ca13 (14 listed in DrugCentral).
• Indications: Edema, Hypertensive disorder, Peripheral Edema due to Chronic Heart Failure and Pulmonary Edema due to Chronic Heart Failure.
• ATC code: C03BA04 (Sulfonamides, plain).
• Molecular formula: C14H11ClN2O4S; molecular weight 338.76 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Edema
• Hypertensive disorder
• Peripheral Edema due to Chronic Heart Failure
• Pulmonary Edema due to Chronic Heart Failure

Off-label uses (2)

• Calcium renal calculus
• Diabetes insipidus

Contraindications (47)

• Acute nephropathy
• Acute pancreatitis
• Acutely Decompensated HF Requiring Parenteral Inotropic Therapy
• Anaphylaxis
• Anuria
• Asthma
• Atrioventricular block
• Calculus in biliary tract
• Cardiogenic shock
• Cerebrovascular disease
• Chronic disease of respiratory system
• Chronic heart failure
• Chronic myocardial ischemia
• Complete atrioventricular block
• Conduction disorder of the heart
• Depressive disorder
• Diabetes mellitus type 1
• Diabetes mellitus type 2
• Electroconvulsive therapy
• End stage renal disease
• Epilepsy
• First Degree Atrioventricular Heart Block
• Gout
• Hepatic failure
• Hypercalcemia
• Hypercholesterolemia
• Hyperuricemia
• Hypochloremic alkalosis
• Hypokalemia
• Hypomagnesemia
• + 17 more

Mechanism & targets

• Established pharmacologic class: Thiazide-like Diuretic

Molecular targets (14)

Target	Gene	Action	Activity
Carbonic anhydrase 7	CA7	unknown	Ki 8.55
Carbonic anhydrase 12	CA12	unknown	Ki 8.35
Carbonic anhydrase 5B, mitochondrial	CA5B	unknown	Ki 8.05
Carbonic anhydrase 13	Ca13	unknown	Ki 7.82
Carbonic anhydrase 9	CA9	unknown	Ki 7.64
Carbonic anhydrase 4	CA4	unknown	Ki 6.71
Carbonic anhydrase 1	CA1	unknown	Ki 6.46
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D	NAPEPLD	allosteric modulator	Kd 6.17
Carbonic anhydrase 5A, mitochondrial	CA5A	unknown	Ki 6.04
Carbonic anhydrase 6	CA6	unknown	Ki 5.87
Carbonic anhydrase 2	CA2	unknown	Kd 5.56
Carbonic anhydrase 14	CA14	unknown	Ki 5.38
Carbonic anhydrase 3	CA3	unknown	Ki 4.96
Solute carrier family 12 member 3	SLC12A3	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1960-04-07	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
C03BA04	CARDIOVASCULAR SYSTEM › DIURETICS › LOW-CEILING DIURETICS, EXCL. THIAZIDES › Sulfonamides, plain
C03BB04	CARDIOVASCULAR SYSTEM › DIURETICS › LOW-CEILING DIURETICS, EXCL. THIAZIDES › Sulfonamides and potassium in combination
C03EA06	CARDIOVASCULAR SYSTEM › DIURETICS › DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION › Low-ceiling diuretics and potassium-sparing agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hyponatraemia	442.1
Hypokalaemia	261.2
Renal artery stenosis	103.8
Presyncope	96.1
Lichen planopilaris	95.7
Renal cyst haemorrhage	94.5
Renal impairment	88.8
Meningitis aseptic	84.7
Acute kidney injury	81.1
SARS-CoV-2 antibody test positive	79.7
Abdominal wall haemorrhage	75.7
Vena cava injury	75.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Chlortalidone is on its molecule page.

• Molecular formula: C₁₄H₁₁ClN₂O₄S
• Molecular weight: 338.76 g/mol
• CAS number: 77-36-1
• InChIKey: JIVPVXMEBJLZRO-UHFFFAOYSA-N
• PubChem CID: 2732

NS(=O)(=O)C1=CC(=CC=C1Cl)C1(O)NC(=O)C2=CC=CC=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Chlortalidone used for?

DrugCentral lists the following indications for Chlortalidone: Edema, Hypertensive disorder, Peripheral Edema due to Chronic Heart Failure and Pulmonary Edema due to Chronic Heart Failure.

How does Chlortalidone work?

Its molecular targets in DrugCentral include CA7, CA12, CA5B and Ca13.

When was Chlortalidone first approved?

Chlortalidone was first approved by the FDA in 1960.

What drug class does Chlortalidone belong to?

Chlortalidone is in the Thiazide-like Diuretic class.

What is the chemical formula of Chlortalidone?

Chlortalidone has the molecular formula C14H11ClN2O4S and a molecular weight of 338.76 g/mol.

Sources

• DrugCentral drug card 625 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1055 — compound record and bioactivity
• PubChem CID 2732 — chemical identifiers
• DrugBank DB00310 — drug record
• FDA UNII Q0MQD1073Q — substance identity
• DailyMed: FDA labels for Chlortalidone — current prescribing information (label search)
• UniProt P43166 (CA7) — target protein
• UniProt O43570 (CA12) — target protein
• UniProt Q9Y2D0 (CA5B) — target protein
• UniProt Q16790 (CA9) — target protein
• UniProt P22748 (CA4) — target protein
• UniProt P00915 (CA1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.